Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation—data from the prospective IVEPSA study

by Eleni Kampylafka, David Simon, Isabelle d’Oliveira, Christina Linz, Veronika Lerchen, Matthias Englbrecht, Juergen Rech, Arnd Kleyer, Michael Sticherling, Georg Schett, Axel J. Hueber
Published 2019-07-01

Secukinumab leads to shifts from stage-based towards response-based disease clusters—comparative data from very early and established psoriatic arthritis

by Eleni Kampylafka, Koray Tascilar, Veronika Lerchen, Christina Linz, Maria Sokolova, Ana Zekovic, Arnd Kleyer, David Simon, Jürgen Rech, Michael Sticherling, Georg Schett, Axel J. Hueber
Published 2020-09-01

Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSA...

by Eleni Kampylafka, Isabelle d’Oliveira, Christina Linz, Veronika Lerchen, Fabian Stemmler, David Simon, Matthias Englbrecht, Michael Sticherling, Jürgen Rech, Arnd Kleyer, Georg Schett, Axel J. Hueber
Published 2018-07-01